Aduro Biotech, Inc.
Brief Description
Aduro is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations. The company’s lead technology platforms are based on LADD (live, attenuated, double-deleted Listeria mononcytogenes) and CDNs (cyclic dinucleotides). Both are proprietary platforms. LADD strains have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity.
Timeline
- 2008. Aduro Biotech founded.
- 2011. Aduro Biotech licenses technology developed at UC Berkeley, including attenuated Listeria monocytogenes mutants and methods to engineer these bacteria to stimulate the immune system as vaccines for immunotherapy.
- 2016. An investment of $7.5 million by Aduro Biotech created a UC Berkeley Immunotherapeutics and Vaccine Research Initiative (IVRI), which brings infectious disease, cancer, and immunology experts from academia and industry together to propel basic and early applied research toward weaponizing the body's immune system against disease.
- 2018. Launch of the Aduro Biotech-UC Berkeley Underrepresented Postdoctoral Fellowship Program in the UC Berkeley College of Chemistry supports researchers from diverse backgrounds, and builds a pipeline of scientific talent for Aduro Biotech R&D laboratories.
- 2020. Aduro Biotech merges with Chinook Therapeutics. The combined company operates as Chinook Therapeutics.
Inventor
Dan Portnoy, David Raulet, Russell Vance
Tech Category
- Medical Therapeutics
In the News
- Aduro Biotech and Chinook Therapeutics Announce Merger 6/2/20
- Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer 2/6/20
- Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents 8/9/17
- Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer 1/9/17
- Aduro Biotech’s Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce 9/26/16
- Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors 5/12/16
- Aduro Biotech to Acquire BioNovion 9/25/15
- Aduro Biotech Announces Close of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Concurrent Private Placement 4/20/15
- Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology 3/30/15
- Aduro receives orphan drug designation for CRS-207 in Mesothelioma 3/26/15
- Aduro BioTech Receives Breakthrough Designation from FDA for Innovative Pancreatic Cancer Combination Therapy 7/21/14
- Aduro Biotech Secures $55M Series C financing 6/11/14
- Aduro Presents Preclinical Data on Enhanced Anti-Tumor Activity with Small-Molecule Immunotherapy Program 11/14/13
- Aduro BioTech acquires GVAX from BioSante Pharma 3/25/13
- Aduro BioTech's Clinical Results on Therapeutic Cancer Vaccines 2/7/12
© 2022 Regents of the University of California. All Rights Reserved.